SCHEMBL20134880

SCHEMBL20134880

C[C@]1(c2ccc(C(=O)O)cc2)NC(=O)NC1=O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.55
KMT2A Q03164 1/20 0.55
LMNA P02545 1/20 0.48
TNKS O95271 1/20 0.47
TP53 P04637 1/20 0.41
TSHR P16473 1/20 0.41
HPGD P15428 1/20 0.40
MMP2 P08253 2/20 0.40
MMP9 P14780 2/20 0.40
ALDH1A1 P00352 2/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
METAP1 P53582 1/20 0.39
AKR1B1 P15121 1/20 0.39
CACNA1F O60840 1/20 0.38
MAPT P10636 1/20 0.38
CYP2C9 P11712 1/20 0.38
HTR2A P28223 1/20 0.38
HRH1 P35367 1/20 0.38
SCN1A P35498 1/20 0.38
SCN4A P35499 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4308515 1.00 MEN1 (0.55) MEN1KMT2ALMNATNKSTP53
SCHEMBL7969160 0.81 MEN1 (0.50) MEN1KMT2ALMNATNKSMMP2
SCHEMBL20134909 0.80 LMNA (0.49) MEN1KMT2ALMNATNKSHPGD
SCHEMBL542865 0.80 ALDH1A1 (0.59) MEN1KMT2ALMNATNKSMMP2
SCHEMBL4384456 0.80 ALDH1A1 (0.59) MEN1KMT2ALMNATNKSMMP2
SCHEMBL4384462 0.80 ALDH1A1 (0.59) MEN1KMT2ALMNATNKSMMP2
Hydrochloric Acid SCHEMBL8477570 0.79 KMT2A (0.55) MEN1KMT2ALMNATNKSMMP2
Hydrochloric Acid SCHEMBL8476327 0.79 KMT2A (0.55) MEN1KMT2ALMNATNKSMMP2
Hydrochloric Acid SCHEMBL8524650 0.79 KMT2A (0.55) MEN1KMT2ALMNATNKSMMP2
SCHEMBL11411411 0.79 CYP2C9 (0.63) TP53TSHRALDH1A1SMN1; SMN2METAP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107922347-B Novel imide derivatives and their use as pharmaceuticals 田边三菱制药株式会社 2022-06-28 CN disclosed
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 US disclosed
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 US disclosed
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-03-14 US disclosed
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-03-14 US disclosed
EP-3321256-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE Mitsubishi Tanabe Pharma Corporation (JP) 2018-05-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MMP9, MMP10, MMP1 MEN1 3735/4885KMT2A 2568/4885LMNA 4264/4885
US-10407408-B2 Imide derivatives and use thereof as medicine MMP9, MMP2, MMP1 MEN1 2913/4885KMT2A 2539/4885LMNA 4113/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.